Vesicare 5 mg (Solifenacin Succinate)

Adult dose

The recommended dose for adults (including elderly patients) is 5mg once daily. If necessary, the dose may be increased to a maximum of 10mg once daily. This medicine may be taken with or without food and should be swallowed whole with water. Dosage adjustment is required for the following patients. 1. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment (creatinine clearance>30ml/min). Use with caution in patients with severe renal impairment (creatinine clearance≤30ml/min), and do not exceed 5mg once daily. 2. Patients with hepatic impairment: No dose adjustment is necessary in patients with mild hepatic impairment. Use with caution in patients with moderate hepatic impairment (Child-Pugh class B), and do not exceed 5mg once daily. 3. Patients receiving strong cytochrome P450 3A4 (CYP3A4) inhibitors: Limit the maximum daily dose to 5mg in patients receiving ketoconazole or other strong CYP3A4 inhibitors (e.g., ritonavir, nelfinavir, itraconazole).

This medication should not be used in patients with urinary retention, severe gastrointestinal problems, myasthenia gravis, or angle-closure glaucoma. Additionally, it should be avoided in patients with allergies to this medication or its components, those undergoing hemodialysis, and patients with severe liver or kidney impairment. It contains lactose, so individuals with genetic issues such as galactose intolerance should not take it. Patients at risk of urinary retention or with potential gastrointestinal obstruction or reduced gastrointestinal motility, as well as patients with severe kidney or liver impairment, should use this medication cautiously. When taken with strong CYP3A4 inhibitors, the maximum dosage must be limited, and caution is necessary for patients with certain gastrointestinal disorders or autonomic neuropathy. This medication can frequently cause side effects such as dry mouth, constipation, blurred vision, urinary retention, and dry eyes, with dry mouth and constipation being particularly common. In severe cases, serious gastrointestinal issues such as bowel occlusion or ileus may occur, so if any abnormal symptoms arise, medical advice should be sought immediately. Rarely, it can cause serious allergic reactions such as angioedema or anaphylaxis; in such cases, administration should be stopped immediately, and treatment should be sought. Caution is advised when driving or operating machinery, as drowsiness or blurred vision may occur. When used in conjunction with other anticholinergic medications, its effects may be potentiated or side effects may worsen, so consultation with a healthcare professional is necessary. This drug is mainly metabolized in the liver; therefore, dosage adjustments are needed in patients with compromised liver function or those taking strong CYP3A4 inhibitors. Women who are pregnant or breastfeeding should consult a doctor before using this medication, and especially during breastfeeding, use should be avoided. The safety and efficacy in children have not been established, therefore it is not administered to pediatric patients. In cases of overdose, symptoms such as headache, dizziness, drowsiness, and blurred vision may occur, and immediate medical attention should be sought for appropriate treatment. Special caution is needed for patients with heart disease or risk factors for QT prolongation.

• dry mouth
• constipation
• blurred vision
• urinary retention
• dry eyes
• nausea
• dyspepsia
• upper abdominal pain
• vomiting
• urinary tract infection

This medication should be stored in a tightly sealed container to prevent air or moisture from entering. It is best stored at room temperature between 1 and 30 degrees Celsius to maintain the medication's efficacy and prevent deterioration.

Appearance

Bright yellow round film-coated tablet

Package unit

30 tablets/bottle, 100 tablets/bottle